WEKO3
アイテム
Reduction rate of anti-acetylcholine receptor antibody titer levels is an early prognostic indicator for myasthenia gravis
https://kagawa-u.repo.nii.ac.jp/records/2000375
https://kagawa-u.repo.nii.ac.jp/records/2000375169884aa-f45e-4b92-9aab-5ca12404f4d4
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
本文 (508 KB)
|
.png)
|
|
|
内容の要旨 (95 KB)
|
|
|
|
審査の結果の要旨 (101 KB)
|
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-04-11 | |||||||||||
| タイトル | ||||||||||||
| タイトル | Reduction rate of anti-acetylcholine receptor antibody titer levels is an early prognostic indicator for myasthenia gravis | |||||||||||
| 言語 | en | |||||||||||
| 言語 | ||||||||||||
| 言語 | eng | |||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||||||
| 資源タイプ | doctoral thesis | |||||||||||
| アクセス権 | ||||||||||||
| アクセス権 | open access | |||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||
| 著者 |
濱田, 康宏
× 濱田, 康宏
WEKO
4212
|
|||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Abstract | |||||||||||
| 内容記述 | Background: A realistic treatment goal for myasthenia gravis (MG) is achieving minimal manifestations or better status with prednisolone at ≤5 mg/day (MM-or-better-5 mg), considering a patient's health-related quality of life. Prognosis prediction during the early phases of immunotherapies might be critical for determining subsequent treatment strategies; however, the appropriate biomarkers remain unknown. | |||||||||||
| 言語 | en | |||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Abstract | |||||||||||
| 内容記述 | Aim: This study aimed to clarify whether the reduction rate of anti-acetylcholine receptor antibody (RR-AChR Ab) titer levels is a useful biomarker for predicting MM-or-better-5 mg achievement. | |||||||||||
| 言語 | en | |||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Abstract | |||||||||||
| 内容記述 | Methods: We retrospectively investigated patients with MG and AChR Abs who received immunotherapy for the first time. The RR-AChR Ab titer levels were calculated in the early (within 30 days), middle (31–60 days), and late (61–100 days) periods after starting immunotherapies. A receiver operating characteristic (ROC) curve was generated to determine an appropriate cutoff value for RR-AChR Abs to achieve an MM-or-better-5 mg. | |||||||||||
| 言語 | en | |||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Abstract | |||||||||||
| 内容記述 | Results: Of 53 patients, 24 (45%) achieved MM-or-better-5 mg after 1 year. For the early period, the RR-AChR Ab cutoff value to predict MM-or-better-5 mg was 1.68%/day with an area under the curve (AUC) of 0.75 (sensitivity, 85%; specificity, 70%). However, the middle and late posttreatment AUC values did not predict MM-or-better-5 mg achievement. | |||||||||||
| 言語 | en | |||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Abstract | |||||||||||
| 内容記述 | Conclusion: The RR-AChR Ab might be an appropriate prognostic biomarker during the early period of MM-or-better-5 mg achievement. In the era of early fast-acting treatment strategies, the RR-AChR Ab trend after starting immunotherapies may guide the subsequent treatment choices. | |||||||||||
| 言語 | en | |||||||||||
| 学位名 | ||||||||||||
| 言語 | ja | |||||||||||
| 学位名 | 博士（医学） | |||||||||||
| 学位授与機関 | ||||||||||||
| 学位授与機関識別子Scheme | kakenhi | |||||||||||
| 学位授与機関識別子 | 16201 | |||||||||||
| 言語 | ja | |||||||||||
| 学位授与機関名 | 香川大学 | |||||||||||
| 言語 | en | |||||||||||
| 学位授与機関名 | Kagawa University | |||||||||||
| 学位授与年月日 | ||||||||||||
| 学位授与年月日 | 2024-03-24 | |||||||||||
| 学位授与番号 | ||||||||||||
| 学位授与番号 | 甲第854号 | |||||||||||
| 権利 | ||||||||||||
| 言語 | en | |||||||||||
| 権利情報 | © 2024 The Authors. Neurology and Clinical Neuroscience published by Japanese Society of Neurology and John Wiley & Sons Australia, Ltd. | |||||||||||
| 権利 | ||||||||||||
| 言語 | en | |||||||||||
| 権利情報Resource | https://creativecommons.org/licenses/by/4.0/ | |||||||||||
| 権利情報 | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | |||||||||||
| 関連サイト | ||||||||||||
| 関連タイプ | isVersionOf | |||||||||||
| 識別子タイプ | DOI | |||||||||||
| 関連識別子 | https://doi.org/10.1111/ncn3.12793 | |||||||||||
| 著者版フラグ | ||||||||||||
| 出版タイプ | P | |||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_fa2ee174bc00049f | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | anti-acetylcholine receptor antibodies | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | fast-acting treatment | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | minimal manifestations | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | myasthenia gravis | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | prognostic prediction | |||||||||||
